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Radiolabelled monoclonal antibodies (MCAs)
which recognise tumour-associated antigens are
being used increasingly for radioimmunolocalisation
(RIL) and trials of treatment for various malig-
nancies, (Miller et al., 1982, 1983; Foon et al., 1984;
Dillman & Royston, 1984). The majority of these
MCAs are murine.
We have previously reported on the use of the
mouse monoclonal antibody UJ13A for in vivo
radioimmunolocalisation of gliomas in humans,
(Richardson et al., 1985), and there has been a
recent report of the treatment of a glioma using
MCA-linked 1311 -irradiation (Epenetos et al.,
1985).
We report here pre-existing anti-mouse immuno-
globulin activity in the serum of a patient under-
going RIL. A 38-year old man with a parietal
gliosarcoma and no significant exposure to mice
was given an i.v. injection of radiolabelled control
and specific MCAs: 300pg of mouse MCA HMFG2
(Taylor-Papadimitriou et al., 1981) labelled with
2.06mCi 1311 and 60,ug of UJ13A (Allan et al.,
1983) labelled with 0.41 mCi 1251.
Throughout the study the patient suffered no ill
effects and urinary and haematological investiga-
tions remained normal. Base line investigations were
normal. These included serum IgM and IgG levels,
tests for rheumatoid factor, an auto-immune profile,
and liver function tests. The patient had no
cutaneous reaction following an i.d. injection of
lOpg (100p1) of UJ13A prior to RIL.
A plasma sample of the two radiolabelled
antibodies taken 10 minutes post-injection was
passed through a Sephacryl S300 superfine gel
(Pharmacia). Both the 1311 and 1251 conjugates
eluted significantly earlier than the IgG peak,
(Figure 1), indicating the label to be in a higher
molecular weight form than the monomeric
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Figure 1 The elution of 13II-control (---)
and 125I-specific (----) MCA from a Sephacryl S300
(Pharmacia) gel in relation to the plasma profile ( )
at 280nm. One ml fractions were counted in a dual
channel well scintillation counter and correction made
for channel cross-over. Both radiolabels elute before
the IgG peak. Both MCAs were of the IgG1 isotype.
radiolabelled IgG antibody. Figure 2 shows the
elution of radiolabelled MCA in a different patient
who had no anti-mouse response.
Incubation in vitro of the specific 131I-labelled
MCA with a pre-injection plasma sample and
subsequent passage through a Sephacryl S300 gel
column showed the majority of the radioactivity to
elute significantly in advance of the IgG peak, thus
paralleling the in vivo behaviour of the injected
antibodies (Figure 3).
Plasma taken before injection of the antibodies
was pre-cleared in vitro by incubation with mouse
IgG (Sigma) prior to adding 131I-specific MCA, the
elution of the mouse radiolabelled MCA then
coincided with the IgG peak, indicating that the
murine MCA now remained as the monomer
(Figure 4).
Haemagglutination tests on the pre-injection
serum using appropriately sensitised red cells
confirmed the presence of a pre-existing anti-mouse
© The Macmillan Press Ltd., 1986290 A.G. DAVIES et al.




















Figure 2 The elution of the 2 radiolabelled MCAs in
a patient who had no anti-mouse activity in the serum.
Both MCAs elute with the IgG fraction. This patient
was representative of all other patients with no
anti-mouse activity who were studied. Plasma profile
( ); 12min post-injection 125I HMFG2 (----); 52h





















Figure 3 Following incubation for 30min of a pre-
injection serum sample from patient RM with radio-
labelled specific MCA, the radiolabel adopts a
higher molecular weight form suggesting immune
complex formation, and elutes considerably earlier
( ) than the IgG peak. The area under the curve
represents 90% of the activity loaded onto the column.
Plasma profile ( ).
immunoglobulin. A six-times washed Group 0,
RhD, Wrb red cell suspension was sensitised with a
predetermined sub-agglutinating dose of one of the
following antibody preparations: (i) Human IgG:
(incomplete anti-D); (ii) Bric 14.2/lAB: a mouse
monoclonal anti-Wrb, lgG2a subclass, (Ridgwell et
al., 1983); (iii) Bric 20.3: a mouse monoclonal anti-
Wrb, 1gM subclass, (D. Ansteee, personal com-
munication).
A sensitised red blood cell suspension was diluted
to 5% in PBS. One drop was added to 2 drops of
the patient's serum, centrifuged for 10 sec, and
agglutination observed macioscopically.













Figure 4 Pre-clearing the patient's serum with mouse
IgG (Sigma) prior to incubation with radiolabelled
MCA results in the MCA remaining in its monomeric
form ( --), and eluting with the IgG fraction.
Plasma profile ( ); elution profile of 131 labelled
MAB incubated with normal plasma or PBS buffer
The patient's serum reacted very strongly with
Bric 14 sensitised cells (mouse IgG), unconvincingly
with Bric 20 (mouse IgN4) and not at all with
incomplete anti-D. All appropriate controls
behaved as anticipated. Thirteen other patients with
gliomas were studied and two strongly positive
reactions were seen. No such reaction was observed
in seventeen controls. Furthermore, a positive
response did not correlate with blood group.
The pharmacokinetics of the injected MCAs in
this patient (RM), did not differ significantly from
10 other patients studied. The clearance from the
blood was biphasic. The fast component of the
half-life in serum was 3.6h for both antibodies and
the slow component was 58 and 63 h for the
specific and non-specific antibodies respectively.
This is not significantly different from a mean of
4.5+4.9 and 62+ 15h for the fast and slow half-life
components of the specific MCA in 7 other patients
studied.
Comments It has been known for some years that
individuals may possess antibodies to various
animal proteins (Rothberg & Farr, 1965), but the
introduction of clinical studies with MCAs now
means that specific anti-mouse reactivity becomes
relevant (Hunter et al., 1984).
Other workers have described human anti-mouse
serological responses in patients following injection
of murine MCAs (Miller et al., 1982). These
immune responses have been reported in 50% of
patients with melanoma that were given repeatedly
large doses of a MCA. These responses consisted of
both IgG and IgM (Oldham et al., 1984).
There are few reports in the literature concerning
the presence of pre-existing anti-mouse activity in
A
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the serum of patients undergoing RIL, and this
phenomenon has not been related to skin test
positivity (Schroff et al., 1985). Primus et al. (1980),
using goat heteroantisera to carcinoembryonic
antigen, have demonstrated pre-existing anti-goat
IgG in scveral patients.
The high molecular weight eluates seen in the
serum of patient RM suggest the formation of
immune complexes. Similar elution profiles were
seen by James et al. (1971) in renal transplant
recipients given equine anti-lymphocyte globulin. It
has previously been observed in studies of RIL that
immune complexes (ICs) may form when there is
circulating free antigen (Goldenberg et al., 1978).
These ICs did not seem to interfere with the success
of the RIL in the circumstances studied (Primus &
Goldenberg, 1980). Of more importance, however,
would be the consequence of administering a large
quantity of animal antibody to an individual
possessing pre-existing anti-species immunoglobulin,
as might occur in attempted therapy. This might
result in serum sickness in such a susceptible
patient (Oldham et al., 1984), together with altered
pharmacokinetics of potentially therapeutic
conjugates.
The reported effects of anti-mouse activity on
MCA pharmacokinetics are variable. In the
treatment of certain leukaemias and lymphomas,
the production of anti-mouse antibodies is said to
effectively neutralise any clinical effects of the
therapy (Dillman & Royston, 1984). The in vivo
handling of radiolabelled MCAs in patients with
melanoma who developed an anti-mouse response
following repeated injections is not so clear. Oldham
et al. (1984), reported unaltered pharmacokinetics
but Larson et al. (1983), using a different anti-
melanoma MCA, observed an increase in the rate
of clearance from the circulation with an increase
in liver uptake and a decrease in tumour uptake.
An immune response in a sensitised individual to a
radiolabelled MCA may result in its accelerated
catabolism and dehalogenation, with rapid excretion
of most of the unbound radionuclide within 24h
(J. Kemshead unpublished observation).
Patients with various malignancies, including
gliomas, are known to produce a range of
heterophile antibodies, (Pfreundschuh et al. 1978),
which may explain the present observations. The
incidence of naturally occurring anti-mouse activity
in the serum of cancer patients remains to be
established. Our observation of this activity in 20%
of a small series of glioma patients sera may
suggest that this phenomenon is more common
than previously suggested. The consequence of
complex formation, should it occur, are likely to
differ with each patient, the type of malignancy and
with the MCA used. In view of these facts, and our
present findings, we would advise testing for such
antibodies against the particular immunoglobulin
which is to be used for in vivo immunotargeting,
especially if repeat injections or large doses are
contemplated. The usual intradermal skin test (for
hypersensitivity) is probably inappropriate, and
direct serological testing is suggested.
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